Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Calogero Vetro

Showing results (41-50 of 61) with videos related to

Pageof 7
Sort By:
Haematologica|April 9, 2026
Disease course of <i>FLT3</i> mutated extramedullary acute myeloid leukemia and efficacy of gilteritinibFrancesco Angotzi, Erika Borlenghi, Chiara Sartor, et al.
Clinical Case Reports|July 20, 2023
A case of high-risk AML in a patient with advanced systemic mastocytosisManlio Fazio, Calogero Vetro, Uroš Markovic, et al.
Hematology Reports|October 28, 2025
Vitamin K Antagonists (VKAs) and Novel Oral Anticoagulants (NOACs) Safety Comparison Based on Data from EudraVigilance DatabasePier Paolo Olimpieri, Fanny Erika Palumbo, Gaetano Giuffrida, et al.
Frontiers in Pharmacology|December 13, 2021
Off-Label Use of Venetoclax in Patients With Acute Myeloid Leukemia: Single Center Experience and Data From Pharmacovigilance DatabaseLucia Gozzo, Calogero Vetro, Serena Brancati, et al.
Oncotarget|September 17, 2016
The prognostic value of the myeloid-mediated immunosuppression marker Arginase-1 in classic Hodgkin lymphomaAlessandra Romano, Nunziatina Laura Parrinello, Calogero Vetro, et al.
Healthcare (Basel, Switzerland)|May 27, 2023
Severe Gastrointestinal Toxicity Following the Use of Gilteritinib: A Case Series and Analysis of Postmarketing Surveillance DataLucia Gozzo, Antonella Nardo, Serena Brancati, et al.
Journal of Clinical Medicine|July 27, 2024
Early Access for Medicines in ITALY: The Case of Ruxolitinib for Patients with Graft-Versus-Host DiseaseLucia Gozzo, Salvatore Leotta, Giovanni Luca Romano, et al.
Hematological Oncology|January 13, 2026
NPM1 and IDH1/2 Mutations Show Limited Prognostic Impact in Relapsed/Refractory AML: Evidence From the AVALON CohortCalogero Vetro, Irene Azzali, Elisabetta Petracci, et al.
Pharmaceuticals (Basel, Switzerland)|December 31, 2025
Safety of Drugs Used in Difficult-to-Treat Epileptic Syndromes: A Disproportionality Analysis Using the Eudravigilance DatabaseArianna Scala, Teresa Angela Trunfio, Chiara Pennisi, et al.
Leukemia|March 3, 2021
Dactinomycin induces complete remission associated with nucleolar stress response in relapsed/refractory NPM1-mutated AMLIlaria Gionfriddo, Lorenzo Brunetti, Federica Mezzasoma, et al.
Pageof 7

Showing results (41-50 of 61) with videos related to

Sort By:
Pageof 7
Haematologica|April 9, 2026
Disease course of <i>FLT3</i> mutated extramedullary acute myeloid leukemia and efficacy of gilteritinibFrancesco Angotzi, Erika Borlenghi, Chiara Sartor, et al.
Clinical Case Reports|July 20, 2023
A case of high-risk AML in a patient with advanced systemic mastocytosisManlio Fazio, Calogero Vetro, Uroš Markovic, et al.
Hematology Reports|October 28, 2025
Vitamin K Antagonists (VKAs) and Novel Oral Anticoagulants (NOACs) Safety Comparison Based on Data from EudraVigilance DatabasePier Paolo Olimpieri, Fanny Erika Palumbo, Gaetano Giuffrida, et al.
Frontiers in Pharmacology|December 13, 2021
Off-Label Use of Venetoclax in Patients With Acute Myeloid Leukemia: Single Center Experience and Data From Pharmacovigilance DatabaseLucia Gozzo, Calogero Vetro, Serena Brancati, et al.
Oncotarget|September 17, 2016
The prognostic value of the myeloid-mediated immunosuppression marker Arginase-1 in classic Hodgkin lymphomaAlessandra Romano, Nunziatina Laura Parrinello, Calogero Vetro, et al.
Healthcare (Basel, Switzerland)|May 27, 2023
Severe Gastrointestinal Toxicity Following the Use of Gilteritinib: A Case Series and Analysis of Postmarketing Surveillance DataLucia Gozzo, Antonella Nardo, Serena Brancati, et al.
Journal of Clinical Medicine|July 27, 2024
Early Access for Medicines in ITALY: The Case of Ruxolitinib for Patients with Graft-Versus-Host DiseaseLucia Gozzo, Salvatore Leotta, Giovanni Luca Romano, et al.
Hematological Oncology|January 13, 2026
NPM1 and IDH1/2 Mutations Show Limited Prognostic Impact in Relapsed/Refractory AML: Evidence From the AVALON CohortCalogero Vetro, Irene Azzali, Elisabetta Petracci, et al.
Pharmaceuticals (Basel, Switzerland)|December 31, 2025
Safety of Drugs Used in Difficult-to-Treat Epileptic Syndromes: A Disproportionality Analysis Using the Eudravigilance DatabaseArianna Scala, Teresa Angela Trunfio, Chiara Pennisi, et al.
Leukemia|March 3, 2021
Dactinomycin induces complete remission associated with nucleolar stress response in relapsed/refractory NPM1-mutated AMLIlaria Gionfriddo, Lorenzo Brunetti, Federica Mezzasoma, et al.
Pageof 7